<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5053992</article-id><article-id pub-id-type="doi">10.3389/fonc.2016.00212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>D&#x02019;Souza</surname><given-names>Neil M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/370264"/></contrib><contrib contrib-type="author"><name><surname>Fang</surname><given-names>Penny</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Logan</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jinzhong</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/367403"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/116407"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/300300"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center</institution>, <addr-line>Houston, TX</addr-line>, <country>USA</country></aff><aff id="aff2"><sup>2</sup><institution>Baylor College of Medicine</institution>, <addr-line>Houston, TX</addr-line>, <country>USA</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Kerrie Leanne McDonald, University of New South Wales, Australia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Justin Lathia, Cleveland Clinic Lerner College of Medicine, USA; Eric Hau, St George Hospital, Australia</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Jing Li, <email>jing.li@mdanderson.org</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Neuro-Oncology, a section of the journal Frontiers in Oncology</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>6</volume><elocation-id>212</elocation-id><history><date date-type="received"><day>02</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 D&#x02019;Souza, Fang, Logan, Yang, Jiang and Li.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>D&#x02019;Souza, Fang, Logan, Yang, Jiang and Li</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Malignancies of the central nervous system (CNS), particularly glioblastoma and brain metastases from a variety of disease sites, are difficult to treat despite advances in multimodality approaches consisting of surgery, chemotherapy, and radiation therapy (RT). Recent successes of immunotherapeutic strategies including immune checkpoint blockade (ICB) <italic>via</italic> anti-PD-1 and anti-CTLA-4 antibodies against aggressive cancers, such as melanoma, non-small cell lung cancer, and renal cell carcinoma, have presented an exciting opportunity to translate these strategies for CNS malignancies. Moreover, <italic>via</italic> both localized cytotoxicity and systemic proinflammatory effects, the role of RT in enhancing antitumor immune response and, therefore, promoting tumor control is being re-examined, with several preclinical and clinical studies demonstrating potential synergistic effect of RT with ICB in the treatment of primary and metastatic CNS tumors. In this review, we highlight the preclinical evidence supporting the immunomodulatory effect of RT and discuss the rationales for its combination with ICB to promote antitumor immune response. We then outline the current clinical experience of combining RT with ICB in the treatment of multiple primary and metastatic brain tumors. Finally, we review advances in characterizing and modifying tumor radioimmunotherapy responses using biomarkers and microRNA (miRNA) that may potentially be used to guide clinical decision-making in the near future.</p></abstract><kwd-group><kwd>immune checkpoint blockade</kwd><kwd>immunotherapy</kwd><kwd>radiotherapy</kwd><kwd>CTLA-4</kwd><kwd>PD-1</kwd><kwd>glioblastoma</kwd><kwd>brain metastases</kwd><kwd>brain neoplasms</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="89"/><page-count count="8"/><word-count count="6491"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Recent advances in the field of tumor immunology, such as the discovery of monoclonal antibodies targeting immune checkpoints, have opened a new frontier in the fight against cancer. These monoclonal antibodies recognize and inhibit immune suppressive functions mediated by cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) receptors to promote immune-mediated antitumor activity (<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>). In the setting of metastatic melanoma, non-small cell lung cancer (NSCLC), Hodgkin&#x02019;s lymphoma, and renal cell carcinoma (RCC), these agents achieved significant improvement in clinical responses and survival as monotherapies, but only in limited subsets of patients (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>). In order to broaden clinical utility and efficacy, recent investigations have focused on combination schemes that provide immune activation, while counteracting inhibitory checkpoint signals. Radiation therapy (RT) has traditionally been perceived to be a local treatment strategy with potentially immunosuppressive effects (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B9" ref-type="bibr">9</xref>). However, recent data suggests that RT can trigger the &#x0201c;abscopal effect,&#x0201d; which describes treatment response in tumors outside the radiation fields through systemic immune-mediated antitumor effects (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>). Other types of immunostimulatory effects of RT have been observed in preclinical studies, and recent clinical studies exploring the role of RT in combination with immunotherapy have shown synergism between these two treatment modalities (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>).</p><p>The brain has traditionally been considered an immunoprivileged entity with most systemic therapies demonstrating minimal to no intracranial activity. While recent advances in systemic therapy have significantly improved patient outcomes including survival, treatment of brain metastasis continues to represent a unique challenge, particularly for patients with neurotropic primaries, such as melanoma, NSCLC, and breast cancer (<xref rid="B18" ref-type="bibr">18</xref>). Similar challenges exist in the treatment of primary central nervous system (CNS) malignancies, such as glioblastoma, which is highly invasive and carries a 5-year survival rate of less than 10% (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>).</p><p>Fortunately, recent data have suggested that the CNS does indeed interact with the immune system and is subject to a dynamic regulation <italic>via</italic> proinflammatory and immunosuppressive forces (<xref rid="B21" ref-type="bibr">21</xref>&#x02013;<xref rid="B23" ref-type="bibr">23</xref>). With the development of immune checkpoint blockade (ICB), studies investigating combination therapy of ICB with traditional standard treatment, including RT, have suggested potential synergistic effects in the brain (<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>). In this review, we provide an overview of the immune modulatory effect of RT and rationales for radioimmunotherapy using ICB. We also aim to explore the future outlook of this emerging paradigm as well as the development of new biomarker platforms that can help harness the full potential of this combined approach in the treatment of CNS malignancies.</p></sec><sec id="S2"><title>Preclinical Rationales</title><sec id="S2-1"><title>Immunostimulatory and Systemic Antitumor Effects of Radiation Therapy</title><p>Although radiation has traditionally been considered an immunologically inert process, the recent discovery of immunogenic cell death (ICD), a unique mode of cell death induced by RT or chemotherapy <italic>via</italic> potent host-mediated antitumor response (<xref rid="B28" ref-type="bibr">28</xref>), has suggested otherwise. Cell death occurs differently depending on the identity and maturity of the phagocytic cell, location and manner of phagocytosis, the availability of helper T-lymphocytes, type of death pathway that is triggered, release of immunosuppressive mediators (TGF-&#x003b2;, IL-10), and the immune cells that are exposed to antigens (<xref rid="B29" ref-type="bibr">29</xref>). ICD in particular is primarily defined by unique molecular processes, including the translocation of calreticulin (CRT) to the cell surface, ATP release, upregulation of costimulatory molecules, and the extracellular release of high-mobility group protein B1 (HMG-B1), which enhances antigen cross-presentation and secretion of proinflammatory cytokines (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p><p>Although RT has been speculated to exert immunosuppressive effects <italic>via</italic> increased TGF-beta expression, M2 macrophage polarization, and T-regulatory (T-reg) cell recruitment, its immunostimulatory effect is beginning to be understood (<xref rid="B31" ref-type="bibr">31</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>). Ionizing radiation has been shown to increase translocation and expression of CRT (<xref rid="B35" ref-type="bibr">35</xref>) and promote gene transcription of proinflammatory factors <italic>via</italic> HMG-B1 (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>), which are the essential components of ICD, as well as reduce production of immune suppressive cytokines and increase expression of MHC-I and synthesis of novel peptides for cytotoxic T cell recognition (<xref rid="B38" ref-type="bibr">38</xref>). Moreover, RT has been shown to promote re-oxygenation and decrease interstitial fluid pressure within the tumor microenvironment, improving immune cell recruitment and infiltration into irradiated tumor (<xref rid="B39" ref-type="bibr">39</xref>). Finally, RT induces the release of tumor-associated antigens (TAAs), diversifying the TCR (T-cell receptor) repertoire of infiltrating CTLs and leading to increased efficacy of CTLs (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Notably, these cancer-specific and stromal-associated responses occur simultaneously and define radiation-induced immunogenicity of the tumor cells. Preclinical studies have clearly suggested that radiation, although conventionally perceived as a local therapy, can potentially exert systemic antitumor effects at least through both cancer cell intrinsic and tumor microenvironmental modulations. These mechanisms are illustrated in Figure <xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Immunostimulatory effects of radiation therapy (RT) in combination with immune checkpoint blockade (ICB) in the CNS</bold>. RT and ICB work synergistically to create an immunogenic tumor microenvironment and promote systemic antitumor response. Anti-PD-1 and PD-L1 agents reduce tumor cell-mediated exhaustion signals to CD8<sup>+</sup> CTLs, while anti-CTLA-4 agents block competing co-inhibitory activity of CTLA-4, resulting in increased and persistent T-cell activation. RT triggers immunogenic cell death (ICD) of tumor cells, displacement of calreticulin (CRT) to the cell surface, release of HMG-B1, increased MHC-I expression, and release of tumor-associated antigens (TAAs), with consequent increase in TCR repertoire of infiltrating T-cells. In addition, RT has stromal effects on the tumor microenvironment: increasing oxygenation, infiltration of TILs, and permeability of the blood&#x02013;brain barrier (BBB), while decreasing interstitial fluid pressure. In combination with ICB, RT also reduces activity of T-regs and MDSCs. SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; CTL, cytotoxic T-lymphocyte; PD-1/L1, programmed cell death protein 1/ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DC, dendritic cell; TIL, tumor-infiltrating lymphocyte; TAA, tumor-associated antigen; MHC, major histocompatibility complex; TCR, T-cell receptor; MDSC, myeloid-derived suppressor cell; HMG-B1, high mobility group box 1.</p></caption><graphic xlink:href="fonc-06-00212-g001"/></fig></sec><sec id="S2-2"><title>Immune Checkpoint Blockade and CNS Tumors</title><p>While the brain has traditionally been considered an immunoprivileged organ system, it is now commonly accepted that dysregulation of immune surveillance may be involved in the pathogenesis and progression of multiple CNS malignancies (<xref rid="B41" ref-type="bibr">41</xref>). Similar to other types of cancers, primary brain tumors can evade immune system detection through multiple immunosuppressive mechanisms, including upregulation of immune checkpoints. For example, PD-L1 has been shown to be upregulated in glioblastoma cells as well as circulating monocytes and macrophages through oncogenic signaling resulting from PTEN loss and modulation of autocrine&#x02013;paracrine IL-10 signaling (<xref rid="B42" ref-type="bibr">42</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>). Increased PD-1 and PD-L1 expression has also been observed in brain metastases and primary CNS lymphomas (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). These findings warrant further exploration of ICB, in particular PD-1 or PD-L1 blockers, in the pathogenesis and treatment of primary and metastatic CNS malignancies.</p><p>Radiation therapy is the pillar of standard therapy for primary and secondary brain tumors. The immunostimulatory effects of RT make it a natural candidate as a synergistic partner with ICB. Indeed, prior preclinical studies have shown survival benefits of radiation with tumor vaccination in glioma mice models (<xref rid="B20" ref-type="bibr">20</xref>). In melanoma, RT has been shown to diversify TCR repertoire of infiltrating CTLs and enhance their function <italic>via</italic> RT-induced release of TAAs (<xref rid="B27" ref-type="bibr">27</xref>). This mechanism worked in concert with an anti-CTLA-4 agent leading to inhibition of T-reg cell function and increased CD8<sup>+</sup> T cell/T-reg ratio. Interestingly, the addition of an anti-PD-L1 agent further prevented T cell exhaustion (<xref rid="B40" ref-type="bibr">40</xref>). In murine glioma models, combining radiation concurrently with anti-PD-1 and anti-CTLA-4 or 4-1BB (a costimulatory molecule) agonist yielded improved survival and increased tumor-infiltrating leukocyte (TIL) population, compared with either modality alone (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B47" ref-type="bibr">47</xref>). The rationale for combining RT with PD-1/PD-L1 blockers is further supported by the observation that local inflammation mediated by RT results in PD-L1 upregulation on cancer cells, macrophages, and dendritic cells (DCs) (<xref rid="B48" ref-type="bibr">48</xref>). Moreover, a recent study in murine melanoma brain metastases (MBM) showed that increasing radiation dose with concurrent immunotherapy improved median and long-term survival and prolonged tumor dormancy (<xref rid="B49" ref-type="bibr">49</xref>). Finally, while the penetrance of ICB agents into the CNS <italic>via</italic> the blood&#x02013;brain barrier (BBB) is not fully known, RT has been shown to increase BBB permeability (<xref rid="B50" ref-type="bibr">50</xref>), further facilitating the penetrance of activated antitumor immune cells and possibly the access of ICB agents as well &#x02013; providing another compelling rationale for combination RT-ICB therapy in the treatment of primary and metastatic CNS tumors (Figure <xref ref-type="fig" rid="F1">1</xref>).</p></sec></sec><sec id="S3"><title>Clinical Studies and Experience</title><p>The combination of RT and ICB has been reported to improve clinical outcomes in multiple metastatic cancers. In metastatic melanoma, potential radiation-induced abscopal responses have been reported in the setting of CTLA-4 blockade (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). The first of such reports was by Postow et al., who described a patient with paraspinal, splenic, and right hilar metastatic disease receiving palliative radiation to the paraspinal lesion with concurrent ipilimumab. Five months after treatment, all lesions demonstrated regression on restaging CT scans (<xref rid="B10" ref-type="bibr">10</xref>). Similar case studies have reported potential clinical benefits of combining radiation with ICB in metastatic melanoma (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>) as well as NSCLC (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>In addition to immunogenic tumors, such as melanoma and NSCLC, the role of radiation combined with ICB has also been investigated in metastatic, castration-resistant prostate cancer. A recently completed phase I/II trial looked at combining ipilimumab and palliative RT to bony disease and found a complete response rate of 2% and stable disease in 12% of patients (<xref rid="B54" ref-type="bibr">54</xref>). Although no difference in overall survival was noted, there were signs of enhanced antitumor activities in the ipilimumab arm with decreased PSA and improved progression-free survival (PFS). It is, however, questionable, whether radiation contributed to these benefits as both the ipilimumab and placebo arms received RT. Another early trial attempted to ask this question by looking at ipilimumab vs. ipilimumab plus RT in metastatic prostate cancer and demonstrated promising clinical response (<xref rid="B55" ref-type="bibr">55</xref>). However, a phase III trial of this regimen in men with previously treated CRPC failed to demonstrate a significant overall survival benefit (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>In the metastatic disease setting, there are multiple ongoing trials combining RT, particularly stereotactic radiosurgery (SRS) or hypofractionated radiation, with immunotherapy in multiple cancer types. At MD Anderson, we are currently investigating different combinations of immune checkpoint blockers with stereotactic body radiation therapy (SBRT) for lung and liver metastasis from multiple primary sites (NCT02239900, NCT02402920, NCT02444741).</p><sec id="S3-1"><title>Brain Metastases</title><p>Clinical evidence supporting the efficacy of combining RT and ICB in the treatment of CNS tumors is primarily garnered from melanoma patients with metastatic disease and is retrospective in nature. Three retrospective single-institution studies have suggested that ipilimumab in combination with RT may be more effective than RT alone in MBM (<xref rid="B57" ref-type="bibr">57</xref>&#x02013;<xref rid="B60" ref-type="bibr">60</xref>). Knisely et al. reviewed the outcomes of 77 patients with MBM who received SRS as well as ipilimumab. Patients who received combination therapy demonstrated improved survival compared with those who received SRS alone (<xref rid="B58" ref-type="bibr">58</xref>). Moreover, a study by Silk et al. explored the benefits of combination therapy vs. RT alone in 70 MBM patients who received brain radiation (either SRS or WBRT) with ipilimumab. Retrospective analysis demonstrated an OS benefit of 19.9&#x02009;months with combination therapy vs. 4.0&#x02009;months for SRS alone, with no associated increase in toxicity with addition of ipilimumab to SRS (<xref rid="B59" ref-type="bibr">59</xref>). An interesting study by Kiess et al. investigated the impact of timing in administration of SRS for brain metastases and ICB on patient outcome. Patients who received SRS before or concurrently with ipilimumab appeared to exhibit improved outcomes in OS and distant intracranial control compared to patients who received radiation after immunotherapy (<xref rid="B60" ref-type="bibr">60</xref>). Notably, responses to ipilimumab therapy in the brain, as in extracranial disease, can be quite durable with some reported response beyond 4&#x02009;years (<xref rid="B61" ref-type="bibr">61</xref>). Given the retrospective and single institutional nature of these studies, caution needs to be taken regarding interpretation of their results. Several prospective early phase clinical trials at multiple institutions are investigating different combination regimens of RT with immune checkpoint blockers in the setting of brain metastases (Table <xref ref-type="table" rid="T1">1</xref>). Results from these studies will one day shed light on the clinical benefit of combining radiation with immunotherapy for the treatment of brain metastases.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><bold>Current clinical trials of immunotherapy with radiation for primary and metastatic CNS malignancy</bold>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Study phase</th><th valign="top" align="left" rowspan="1" colspan="1">Institution/group</th><th valign="top" align="left" rowspan="1" colspan="1">ClinicalTrials.gov ID</th><th valign="top" align="left" rowspan="1" colspan="1">Disease site</th><th valign="top" align="left" rowspan="1" colspan="1">Cohorts</th><th valign="top" align="left" rowspan="1" colspan="1">Planned accrual</th><th valign="top" align="left" rowspan="1" colspan="1">IT mechanism</th><th valign="top" align="left" rowspan="1" colspan="1">Est. completion date</th><th valign="top" align="left" rowspan="1" colspan="1">Primary outcome measure</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">Multi-institutional (CheckMate548)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02667587</td><td align="left" valign="top" rowspan="1" colspan="1">Newly diagnosed glioblastoma</td><td align="left" valign="top" rowspan="1" colspan="1">Nivolumab + temozolomide + RT vs. placebo + temozolomide + RT</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 320</td><td align="left" valign="top" rowspan="1" colspan="1">anti-PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">May 2017</td><td align="left" valign="top" rowspan="1" colspan="1">OS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">III</td><td align="left" valign="top" rowspan="1" colspan="1">Multi-institutional (CheckMate498)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02617589</td><td align="left" valign="top" rowspan="1" colspan="1">Newly diagnosed glioblastoma</td><td align="left" valign="top" rowspan="1" colspan="1">Nivolumab + RT vs. temozolomide + RT</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 550</td><td align="left" valign="top" rowspan="1" colspan="1">anti-PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">October 2019</td><td align="left" valign="top" rowspan="1" colspan="1">OS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">Ludwig Institute for Cancer Research</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02336165</td><td align="left" valign="top" rowspan="1" colspan="1">Newly diagnosed, recurrent glioblastoma</td><td align="left" valign="top" rowspan="1" colspan="1">MEDI4736 vs. MEDI4736 + standard RT vs. MEDI4736 + bevacizumab</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 108</td><td align="left" valign="top" rowspan="1" colspan="1">anti-PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">July 2017</td><td align="left" valign="top" rowspan="1" colspan="1">OS, PFS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I/II</td><td align="left" valign="top" rowspan="1" colspan="1">Northwestern University</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02530502</td><td align="left" valign="top" rowspan="1" colspan="1">Newly diagnosed glioblastoma</td><td align="left" valign="top" rowspan="1" colspan="1">RT + temozolomide + pembrolizumab &#x02192; temozolomide + pembrolizumab</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 50</td><td align="left" valign="top" rowspan="1" colspan="1">anti-PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">March 2018</td><td align="left" valign="top" rowspan="1" colspan="1">Dosage, PFS, OS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">H. Lee Moffitt Cancer Center</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02313272</td><td align="left" valign="top" rowspan="1" colspan="1">Recurrent glioma</td><td align="left" valign="top" rowspan="1" colspan="1">HFSRT + pembrolizumab + bevacizumab</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 32</td><td align="left" valign="top" rowspan="1" colspan="1">anti-PD-1</td><td align="left" valign="top" rowspan="1" colspan="1">June 2017</td><td align="left" valign="top" rowspan="1" colspan="1">Dosage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I/II</td><td align="left" valign="top" rowspan="1" colspan="1">MD Anderson Cancer Center</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02696993</td><td align="left" valign="top" rowspan="1" colspan="1">NSCLC BM</td><td align="left" valign="top" rowspan="1" colspan="1">Nivolumab + SRS; nivolumab + WBRT; nivolumab + ipilimumab + SRS; nivolumab + ipilimumab + WBRT</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 130</td><td align="left" valign="top" rowspan="1" colspan="1">anti-PD-1; anti-CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">April 2020</td><td align="left" valign="top" rowspan="1" colspan="1">Dosage; PFS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">Grupo Espa&#x000f1;ol Multidisciplinar de Melanoma (GEM)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02115139</td><td align="left" valign="top" rowspan="1" colspan="1">Melanoma BM</td><td align="left" valign="top" rowspan="1" colspan="1">Ipilimumab + WBRT</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 66</td><td align="left" valign="top" rowspan="1" colspan="1">anti-CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">October 2016</td><td align="left" valign="top" rowspan="1" colspan="1">1-year survival rate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">University of Michigan Cancer Center</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02097732</td><td align="left" valign="top" rowspan="1" colspan="1">Melanoma BM</td><td align="left" valign="top" rowspan="1" colspan="1">Ipilimumab &#x02192; SRS &#x02192; ipilimumab vs. SRS &#x02192; ipilimumab</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 40</td><td align="left" valign="top" rowspan="1" colspan="1">anti-CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">May 2017</td><td align="left" valign="top" rowspan="1" colspan="1">Local control rate</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">Thomas Jefferson University</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01703507</td><td align="left" valign="top" rowspan="1" colspan="1">Melanoma BM</td><td align="left" valign="top" rowspan="1" colspan="1">Ipilimumab + WBRT vs. ipilimumab + SRS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 24</td><td align="left" valign="top" rowspan="1" colspan="1">anti-CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">November 2017</td><td align="left" valign="top" rowspan="1" colspan="1">Dosage</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">I</td><td align="left" valign="top" rowspan="1" colspan="1">Sidney Kimmel Comprehensive Cancer Center</td><td align="left" valign="top" rowspan="1" colspan="1">NCT01950195</td><td align="left" valign="top" rowspan="1" colspan="1">Melanoma BM</td><td align="left" valign="top" rowspan="1" colspan="1">Ipilimumab + SRS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 30</td><td align="left" valign="top" rowspan="1" colspan="1">anti-CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">December 2016</td><td align="left" valign="top" rowspan="1" colspan="1">Adverse events and safety</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">II</td><td align="left" valign="top" rowspan="1" colspan="1">University Hospital, Lille</td><td align="left" valign="top" rowspan="1" colspan="1">NCT02662725</td><td align="left" valign="top" rowspan="1" colspan="1">Melanoma BM</td><td align="left" valign="top" rowspan="1" colspan="1">Ipilimumab + SRS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>n</italic> = 73</td><td align="left" valign="top" rowspan="1" colspan="1">anti-CTLA-4</td><td align="left" valign="top" rowspan="1" colspan="1">December 2015</td><td align="left" valign="top" rowspan="1" colspan="1">OS</td></tr></tbody></table><table-wrap-foot><p><italic>RT, radiation therapy; PD-1, programmed cell death protein 1; OS overall survival, PFS, progression-free survival; HFSRT, hypofractionated stereotactic radiotherapy; IMRT, intensity-modulated radiation therapy; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; irRC, immune-related response criteria; WBRT, whole brain radiation therapy; NSCLC, non-small cell lung cancer; BM, brain metastases; SRS, stereotactic radiosurgery; MM, metastatic melanoma; SBRT, stereotactic body radiation therapy</italic>.</p></table-wrap-foot></table-wrap></sec><sec id="S3-2"><title>Primary Brain Tumors and Ongoing Clinical Trials</title><p>For primary CNS tumors, such as glioblastoma, several combination approaches with radiation have been explored clinically (<xref rid="B62" ref-type="bibr">62</xref>). For example, immunotherapy in the form of vaccines derived from autologous DCs and pulsed with tumor lysate and various tumor antigens (such as the EGFRvIII vaccine Rindopepimut) have shown some promise in the clinical setting (<xref rid="B20" ref-type="bibr">20</xref>). A randomized phase II trial testing ICT-107, a vaccine composed of autologous DCs and tumor antigens, administered with radiation and temozolomide for newly diagnosed glioblastoma, demonstrated benefit in terms of OS and PFS for a subset of HLA-A2 positive patients (<xref rid="B63" ref-type="bibr">63</xref>).</p><p>Although evidence supporting the combination of ICB and RT for glioblastoma is currently lacking, several clinical trials are underway examining this combination for newly diagnosed and recurrent glioblastoma (Table <xref ref-type="table" rid="T1">1</xref>). Two of these are large multi-institutional trials in phases II and III (NCT02667587, NCT02617589) examining OS in patients given nivolumab in combination with radiation (with/without concurrent temozolomide) for newly diagnosed glioblastoma, while another smaller trial is examining similar combinations with pembrolizumab (NCT02530502). A phase II trial sponsored by the Ludwig Institute is investigating OS in monotherapy with the PD-1 inhibitor durvalumab (MEDI4736) in comparison to combination approaches with standard RT or the VEGF inhibitor bevacizumab. Finally, a phase I trial is examining maximum dosage of pembrolizumab when it is used with combination therapy with bevacizumab and a hypofractionated radiation regimen given over 5&#x02009;days for recurrent glioma. Additional clinical trials investigating combination approaches in the context of primary CNS malignancy will soon be underway.</p></sec><sec id="S3-3"><title>Future Outlook</title><p>Glioblastoma is notorious for employing a wide variety of immunosuppressive strategies to disrupt the function of immune cells, lower immunoglobulin levels, and generate a plethora of immunosuppressive processes, involving TGF-beta, IL-10, MHC-I downregulation, T-regs recruitment, and increased expression of PD-L1 (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B64" ref-type="bibr">64</xref>&#x02013;<xref rid="B68" ref-type="bibr">68</xref>). Development of therapeutics for glioblastoma is complicated by the variability in antigen expression within individual tumors and subtypes. The ability to target the unique signature of tumor-specific mutations and antigens (&#x0201c;neoantigens&#x0201d;) is crucial in effective tumor control, and the expression of these neoantigens has been shown to predict long-term response to ICB in metastatic melanoma and NSCLC (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>). Strategies such as biomarker and microRNA (miRNA) development are under investigation to predict and modulate tumor response to immunotherapy and RT.</p></sec><sec id="S3-4"><title>Biomarker Identification</title><p>Along with clinical trials, current translational research efforts are exploring potential predictive biomarkers for response to immunotherapies in glioblastoma (<xref rid="B71" ref-type="bibr">71</xref>). Increased PD-L1 expression in circulating monocytes has been identified as a biomarker for tumor-induced immunosuppression and a prognostic factor for poor survival. For example, in one study of glioblastoma patients, the median overall survival for high-expressers of PD-L1 was 18.0&#x02009;months compared with 44.7&#x02009;months for low PD-L1 peripheral monocyte expressers (<xref rid="B5" ref-type="bibr">5</xref>). Another example is level of tumor EGFRvIII expression as a biomarker for response to the EGFRvIII vaccine in glioblastoma (<xref rid="B72" ref-type="bibr">72</xref>). Increased peripheral blood levels of CD33<sup>+</sup>HLA-DR<sup>&#x02212;</sup> myeloid-derived suppressor cells (MDSCs), with the potential to induce T-regs and apoptosis in activated lymphocytes as well as secrete immunosuppressive cytokines and oxidizing molecules, have also been reported patients with glioblastoma. RT in combination with ICB has been shown to reduce tumor-associated MDSCs in comparison to single therapy <italic>via</italic> the activity of CD8<sup>+</sup> T cells and tumor necrosis factor (TNF) signaling <italic>in vivo</italic> (<xref rid="B48" ref-type="bibr">48</xref>). Moreover, a diminution in the level of circulating T-regs has shown promise as a biomarker for treatment response to immunotherapies (<xref rid="B73" ref-type="bibr">73</xref>).</p><p>MicroRNAs can act as oncogenes or tumor suppressors through controlling target gene expression and binding of mRNA, and also carry promise as biomarkers (<xref rid="B74" ref-type="bibr">74</xref>). In glioblastoma, tumor miR-21 has been a promising candidate as a biomarker in diagnosis and response to chemotherapies (<xref rid="B75" ref-type="bibr">75</xref>). In the serum, levels of miR-128, miR-320, and miR-574-3p have been found to be elevated (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). Interestingly, the presence of metastatic disease in the brain can be distinguished from glioblastoma <italic>via</italic> the identification of the miR-200 family in cerebrospinal fluid (<xref rid="B78" ref-type="bibr">78</xref>). miRNA can also serve as targets for therapy. Double-stranded miRNA mimics can reinstate activity of tumor suppressor miRNA, and oncogenic miRNAs can be disenabled by single-stranded antisense nucleotides known as &#x0201c;antimiRs&#x0201d; (<xref rid="B79" ref-type="bibr">79</xref>). One example in the CNS is miR-296, which led to reduced tumor volume and angiogenesis in a murine glioma model (<xref rid="B80" ref-type="bibr">80</xref>). Another miRNA, miR-221/222, demonstrated reduced tumor volume in murine melanoma (<xref rid="B79" ref-type="bibr">79</xref>). A potential target for an miRNA mimic in ICB is miR-138, which has been demonstrated to target both CTLA-4 and PD-1, inhibiting tumor-infiltrating T-regs and subsequently releasing the brake set by these immunosuppressive cells within the glioblastoma microenvironment (<xref rid="B81" ref-type="bibr">81</xref>). Whether specific miRNA can be used to predict treatment responses to immunotherapy warrants further investigation.</p><p>Newer techniques, such as multi-parameter flow cytometry, time-of-flight mass cytometry (CyTOF) and whole-repertoire T and B receptor amplification, can be used to characterize the immunologic cellular makeup of primary and metastatic brain lesions at baseline and changes in circulatory immune cell profile during treatment (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). RNAseq transcriptome profiling of tumor samples can quantify the presence of markers, tumor antigens, and certain genes. The latter has demonstrated utility in predicting survival in neuroblastoma and treatment response in breast cancer (<xref rid="B84" ref-type="bibr">84</xref>). Finally, &#x0201c;imaging genomics&#x0201d; or &#x0201c;radiomic&#x0201d; analysis may be a cost-effective and non-invasive strategy to link the radiophenotype of a tumor it its underlying genomic and proteomic characteristics, <italic>via</italic> the high-throughput extraction and analysis of large amounts of radiographic imaging for distinctive features, which can then be mapped to certain genomic and proteomic patterns such that predictive and prognostic classifications may be made (<xref rid="B85" ref-type="bibr">85</xref>&#x02013;<xref rid="B88" ref-type="bibr">88</xref>). Radiomic analysis may be particularly useful to characterize and distinguish radiation necrosis (RN), a potential late adverse effect of high-dose focal irradiation to the brain occurring more frequently in patients receiving ICB (<xref rid="B89" ref-type="bibr">89</xref>), from tumor progression or recurrence and the phenomenon of pseudoprogression. Furthermore, this strategy may be used with traditionally measured biomarkers and miRNA profiles to construct multi-dimensional schemes for prediction of response to combining ICB and RT, development of tailored treatment plans, and assessment of adverse effects of such therapy.</p></sec></sec><sec id="S4"><title>Conclusion</title><p>A new generation of immunotherapeutics, most prominently the immune checkpoint inhibitors, has ushered in a new era of cancer treatment strategies. Despite the effectiveness of these agents, significant limitations remain. Multiple studies have begun to reveal a synergistic effect between ICB and RT, with numerous clinical trials exploring combinatorial strategies in diverse sites of disease. Primary CNS malignancies, such as glioblastoma, and far more commonly metastatic lesions, carry a grim prognosis and stand to gain much benefit from novel combination approaches utilizing RT and ICB. Benefits in terms of survival and intracranial control have been shown in the preclinical setting and are now being tested in various trials. However, many important questions remain to be answered. Nevertheless, with improved understanding of how RT interacts with the immune system, combined strategies that utilize RT with ICB may provide a new and effective to treat CNS malignancies.</p></sec><sec id="S5"><title>Author Contributions</title><p>NMD performed the literature research. All authors helped to write the manuscript.</p></sec><sec id="S6"><title>Conflict of Interest Statement</title><p>JLi received research funding from BMS to support the research expenses of a phase I/II clinical trial with immunotherapy. The rest of the authors report no conflicts of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name></person-group>
<article-title>Radiation with immunotherapy: an emerging combination for cancer treatment</article-title>. <source>J Radiat Oncol</source> (<year>2015</year>) <volume>4</volume>(<issue>4</issue>):<fpage>331</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s13566-015-0217-4</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Peggs</surname><given-names>KS</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group>. <article-title>Checkpoint blockade in cancer immunotherapy</article-title>. <source>Adv Immunol</source> (<year>2006</year>) <volume>90</volume>:<fpage>297</fpage>&#x02013;<lpage>339</lpage>.<pub-id pub-id-type="doi">10.1016/S0065-2776(06)90008-X</pub-id><?supplied-pmid 16730267?><pub-id pub-id-type="pmid">16730267</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>DR</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group>. <article-title>Enhancement of antitumor immunity by CTLA-4 blockade</article-title>. <source>Science</source> (<year>1996</year>) <volume>271</volume>(<issue>5256</issue>):<fpage>1734</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1126/science.271.5256.1734</pub-id><?supplied-pmid 8596936?><pub-id pub-id-type="pmid">8596936</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Tykodi</surname><given-names>SS</given-names></name><name><surname>Chow</surname><given-names>LQ</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>366</volume>(<issue>26</issue>):<fpage>2455</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1200694</pub-id><?supplied-pmid 22658128?><pub-id pub-id-type="pmid">22658128</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><etal/></person-group>
<article-title>Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>366</volume>(<issue>26</issue>):<fpage>2443</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id><?supplied-pmid 22658127?><pub-id pub-id-type="pmid">22658127</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansell</surname><given-names>SM</given-names></name><name><surname>Lesokhin</surname><given-names>AM</given-names></name><name><surname>Borrello</surname><given-names>I</given-names></name><name><surname>Halwani</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>EC</given-names></name><name><surname>Gutierrez</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#x02019;s lymphoma</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>372</volume>(<issue>4</issue>):<fpage>311</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1411087</pub-id><?supplied-pmid 25482239?><pub-id pub-id-type="pmid">25482239</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Chow</surname><given-names>LQM</given-names></name><name><surname>Juergens</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>First-line nivolumab (anti&#x02013;PD&#x02013;1; BMS&#x02013;936558, ONO&#x02013;4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD&#x02013;L1 status</article-title>. <source>J Clin Oncol</source> (<year>2014</year>) <volume>32</volume>(<issue>15 Suppl</issue>):<fpage>8024</fpage>.</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Redman</surname><given-names>BG</given-names></name><name><surname>Kuzel</surname><given-names>TM</given-names></name><name><surname>Harrison</surname><given-names>MR</given-names></name><etal/></person-group>
<article-title>Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial</article-title>. <source>J Clin Oncol</source> (<year>2015</year>) <volume>33</volume>(<issue>13</issue>):<fpage>1430</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1200/JCO.2014.59.0703</pub-id><?supplied-pmid 25452452?><pub-id pub-id-type="pmid">25452452</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Gomez</surname><given-names>D</given-names></name><name><surname>Levy</surname><given-names>L</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Gebremichael</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2014</year>) <volume>89</volume>(<issue>5</issue>):<fpage>1084</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2014.04.025</pub-id><?supplied-pmid 25035212?><pub-id pub-id-type="pmid">25035212</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Barker</surname><given-names>CA</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Kitano</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Immunologic correlates of the abscopal effect in a patient with melanoma</article-title>. <source>N Engl J Med</source> (<year>2012</year>) <volume>366</volume>(<issue>10</issue>):<fpage>925</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1112824</pub-id><?supplied-pmid 22397654?><pub-id pub-id-type="pmid">22397654</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewan</surname><given-names>MZ</given-names></name><name><surname>Galloway</surname><given-names>AE</given-names></name><name><surname>Kawashima</surname><given-names>N</given-names></name><name><surname>Dewyngaert</surname><given-names>JK</given-names></name><name><surname>Babb</surname><given-names>JS</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody</article-title>. <source>Clin Cancer Res</source> (<year>2009</year>) <volume>15</volume>(<issue>17</issue>):<fpage>5379</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0265</pub-id><?supplied-pmid 19706802?><pub-id pub-id-type="pmid">19706802</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeshima</surname><given-names>T</given-names></name><name><surname>Chamoto</surname><given-names>K</given-names></name><name><surname>Wakita</surname><given-names>D</given-names></name><name><surname>Ohkuri</surname><given-names>T</given-names></name><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Shirato</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy</article-title>. <source>Cancer Res</source> (<year>2010</year>) <volume>70</volume>(<issue>7</issue>):<fpage>2697</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2982</pub-id><?supplied-pmid 20215523?><pub-id pub-id-type="pmid">20215523</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siva</surname><given-names>S</given-names></name><name><surname>Macmanus</surname><given-names>MP</given-names></name><name><surname>Martin</surname><given-names>RF</given-names></name><name><surname>Martin</surname><given-names>OA</given-names></name></person-group>. <article-title>Abscopal effects of radiation therapy: a clinical review for the radiobiologist</article-title>. <source>Cancer Lett</source> (<year>2015</year>) <volume>356</volume>(<issue>1</issue>):<fpage>82</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.canlet.2013.09.018</pub-id><?supplied-pmid 24125863?><pub-id pub-id-type="pmid">24125863</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Ng</surname><given-names>B</given-names></name><name><surname>Devitt</surname><given-names>ML</given-names></name><name><surname>Babb</surname><given-names>JS</given-names></name><name><surname>Kawashima</surname><given-names>N</given-names></name><name><surname>Liebes</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2004</year>) <volume>58</volume>(<issue>3</issue>):<fpage>862</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2003.09.012</pub-id><?supplied-pmid 14967443?><pub-id pub-id-type="pmid">14967443</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalbasi</surname><given-names>A</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Haas</surname><given-names>N</given-names></name><name><surname>Vapiwala</surname><given-names>N</given-names></name></person-group>. <article-title>Radiation and immunotherapy: a synergistic combination</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>(<issue>7</issue>):<fpage>2756</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1172/JCI69219</pub-id><?supplied-pmid 23863633?><pub-id pub-id-type="pmid">23863633</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Formenti</surname><given-names>SC</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name></person-group>. <article-title>Combining radiotherapy and cancer immunotherapy: a paradigm shift</article-title>. <source>J Natl Cancer Inst</source> (<year>2013</year>) <volume>105</volume>(<issue>4</issue>):<fpage>256</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1093/jnci/djs629</pub-id><?supplied-pmid 23291374?><pub-id pub-id-type="pmid">23291374</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vatner</surname><given-names>RE</given-names></name><name><surname>Cooper</surname><given-names>BT</given-names></name><name><surname>Vanpouille-box</surname><given-names>C</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name></person-group>. <article-title>Combinations of immunotherapy and radiation in cancer therapy</article-title>. <source>Front Oncol</source> (<year>2014</year>) <volume>4</volume>:<fpage>325</fpage>.<pub-id pub-id-type="doi">10.3389/fonc.2014.00325</pub-id><?supplied-pmid 25506582?><pub-id pub-id-type="pmid">25506582</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owonikoko</surname><given-names>TK</given-names></name><name><surname>Arbiser</surname><given-names>J</given-names></name><name><surname>Zelnak</surname><given-names>A</given-names></name><name><surname>Shu</surname><given-names>HK</given-names></name><name><surname>Shim</surname><given-names>H</given-names></name><name><surname>Robin</surname><given-names>AM</given-names></name><etal/></person-group>
<article-title>Current approaches to the treatment of metastatic brain tumours</article-title>. <source>Nat Rev Clin Oncol</source> (<year>2014</year>) <volume>11</volume>(<issue>4</issue>):<fpage>203</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1038/nrclinonc.2014.25</pub-id><?supplied-pmid 24569448?><pub-id pub-id-type="pmid">24569448</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Gittleman</surname><given-names>H</given-names></name><name><surname>Stetson</surname><given-names>L</given-names></name><name><surname>Virk</surname><given-names>SM</given-names></name><name><surname>Barnholtz-sloan</surname><given-names>JS</given-names></name></person-group>. <article-title>Epidemiology of gliomas</article-title>. <source>Cancer Treat Res</source> (<year>2015</year>) <volume>163</volume>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1007/978-3-319-12048-5_1</pub-id><?supplied-pmid 25468222?><pub-id pub-id-type="pmid">25468222</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neagu</surname><given-names>MR</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name></person-group>. <article-title>An update on the role of immunotherapy and vaccine strategies for primary brain tumors</article-title>. <source>Curr Treat Options Oncol</source> (<year>2015</year>) <volume>16</volume>(<issue>11</issue>):<fpage>54</fpage>.<pub-id pub-id-type="doi">10.1007/s11864-015-0371-3</pub-id><?supplied-pmid 26454859?><pub-id pub-id-type="pmid">26454859</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecci</surname><given-names>PE</given-names></name><name><surname>Heimberger</surname><given-names>AB</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name></person-group>. <article-title>Immunotherapy for primary brain tumors: no longer a matter of privilege</article-title>. <source>Clin Cancer Res</source> (<year>2014</year>) <volume>20</volume>(<issue>22</issue>):<fpage>5620</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0832</pub-id><?supplied-pmid 25398845?><pub-id pub-id-type="pmid">25398845</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>MJ</given-names></name><name><surname>Doose</surname><given-names>JM</given-names></name><name><surname>Melchior</surname><given-names>B</given-names></name><name><surname>Schmid</surname><given-names>CD</given-names></name><name><surname>Ploix</surname><given-names>CC</given-names></name></person-group>. <article-title>CNS immune privilege: hiding in plain sight</article-title>. <source>Immunol Rev</source> (<year>2006</year>) <volume>213</volume>:<fpage>48</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00441.x</pub-id><?supplied-pmid 16972896?><pub-id pub-id-type="pmid">16972896</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivest</surname><given-names>S</given-names></name></person-group>. <article-title>Regulation of innate immune responses in the brain</article-title>. <source>Nat Rev Immunol</source> (<year>2009</year>) <volume>9</volume>(<issue>6</issue>):<fpage>429</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1038/nri2565</pub-id><?supplied-pmid 19461673?><pub-id pub-id-type="pmid">19461673</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>See</surname><given-names>AP</given-names></name><name><surname>Phallen</surname><given-names>J</given-names></name><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Belcaid</surname><given-names>Z</given-names></name><name><surname>Ruzevick</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2013</year>) <volume>86</volume>(<issue>2</issue>):<fpage>343</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.12.025</pub-id><?supplied-pmid 23462419?><pub-id pub-id-type="pmid">23462419</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wainwright</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>AL</given-names></name><name><surname>Dey</surname><given-names>M</given-names></name><name><surname>Balyasnikova</surname><given-names>IV</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name><name><surname>Tobias</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors</article-title>. <source>Clin Cancer Res</source> (<year>2014</year>) <volume>20</volume>(<issue>20</issue>):<fpage>5290</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0514</pub-id><?supplied-pmid 24691018?><pub-id pub-id-type="pmid">24691018</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecci</surname><given-names>PE</given-names></name><name><surname>Ochiai</surname><given-names>H</given-names></name><name><surname>Mitchell</surname><given-names>DA</given-names></name><name><surname>Grossi</surname><given-names>PM</given-names></name><name><surname>Sweeney</surname><given-names>AE</given-names></name><name><surname>Archer</surname><given-names>GE</given-names></name><etal/></person-group>
<article-title>Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function</article-title>. <source>Clin Cancer Res</source> (<year>2007</year>) <volume>13</volume>(<issue>7</issue>):<fpage>2158</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2070</pub-id><?supplied-pmid 17404100?><pub-id pub-id-type="pmid">17404100</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname><given-names>DC</given-names></name><name><surname>Davis</surname><given-names>AA</given-names></name><name><surname>Wainwright</surname><given-names>DA</given-names></name></person-group>
<article-title>Immunotherapy for cancer in the central nervous system: current and future directions</article-title>. <source>Oncoimmunology</source> (<year>2016</year>) <volume>5</volume>(<issue>2</issue>):<fpage>e1082027</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1082027</pub-id><pub-id pub-id-type="pmid">27057463</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name></person-group>
<article-title>Immunogenic cell death in cancer therapy</article-title>. <source>Annu Rev Immunol</source> (<year>2013</year>) <volume>31</volume>:<fpage>51</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-100008</pub-id><pub-id pub-id-type="pmid">23157435</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Ferguson</surname><given-names>T</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group>. <article-title>Immunogenic and tolerogenic cell death</article-title>. <source>Nat Rev Immunol</source> (<year>2009</year>) <volume>9</volume>(<issue>5</issue>):<fpage>353</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1038/nri2545</pub-id><?supplied-pmid 19365408?><pub-id pub-id-type="pmid">19365408</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Senovilla</surname><given-names>L</given-names></name><name><surname>Vitale</surname><given-names>I</given-names></name><name><surname>Vacchelli</surname><given-names>E</given-names></name><name><surname>Adjemian</surname><given-names>S</given-names></name><name><surname>Agostinis</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Consensus guidelines for the detection of immunogenic cell death</article-title>. <source>Oncoimmunology</source> (<year>2014</year>) <volume>3</volume>(<issue>9</issue>):<fpage>e955691</fpage>.<pub-id pub-id-type="doi">10.4161/21624011.2014.955691</pub-id><?supplied-pmid 25941621?><pub-id pub-id-type="pmid">25941621</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dancea</surname><given-names>HC</given-names></name><name><surname>Shareef</surname><given-names>MM</given-names></name><name><surname>Ahmed</surname><given-names>MM</given-names></name></person-group>
<article-title>Role of radiation-induced TGF-beta signaling in cancer therapy</article-title>. <source>Mol Cell Pharmacol</source> (<year>2009</year>) <volume>1</volume>(<issue>1</issue>):<fpage>44</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.4255/mcpharmacol.09.06</pub-id><pub-id pub-id-type="pmid">20336170</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>FH</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Huang</surname><given-names>HL</given-names></name><name><surname>Jung</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><etal/></person-group>
<article-title>Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2007</year>) <volume>68</volume>(<issue>2</issue>):<fpage>499</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.01.041</pub-id><?supplied-pmid 17398016?><pub-id pub-id-type="pmid">17398016</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachikwu</surname><given-names>EL</given-names></name><name><surname>Iwamoto</surname><given-names>KS</given-names></name><name><surname>Liao</surname><given-names>YP</given-names></name><name><surname>DeMarco</surname><given-names>JJ</given-names></name><name><surname>Agazaryan</surname><given-names>N</given-names></name><name><surname>Economou</surname><given-names>JS</given-names></name><etal/></person-group>
<article-title>Radiation enhances regulatory T cell representation</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2011</year>) <volume>81</volume>(<issue>4</issue>):<fpage>1128</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.09.034</pub-id><?supplied-pmid 21093169?><pub-id pub-id-type="pmid">21093169</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellsworth</surname><given-names>S</given-names></name><name><surname>Balmanoukian</surname><given-names>A</given-names></name><name><surname>Kos</surname><given-names>F</given-names></name><name><surname>Nirschl</surname><given-names>CJ</given-names></name><name><surname>Nirschl</surname><given-names>TR</given-names></name><name><surname>Grossman</surname><given-names>SA</given-names></name><etal/></person-group>
<article-title>Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide</article-title>. <source>Oncoimmunology</source> (<year>2014</year>) <volume>3</volume>(<issue>1</issue>):<fpage>e27357</fpage><pub-id pub-id-type="doi">10.4161/onci.27357</pub-id><pub-id pub-id-type="pmid">24790790</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeid</surname><given-names>M</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Fimia</surname><given-names>GM</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Perfettini</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>Calreticulin exposure dictates the immunogenicity of cancer cell death</article-title>. <source>Nat Med</source> (<year>2007</year>) <volume>13</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1038/nm1523</pub-id><?supplied-pmid 17187072?><pub-id pub-id-type="pmid">17187072</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeer</surname><given-names>DW</given-names></name><name><surname>Spanos</surname><given-names>WC</given-names></name><name><surname>Vermeer</surname><given-names>PD</given-names></name><name><surname>Bruns</surname><given-names>AM</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group>. <article-title>Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer</article-title>. <source>Int J Cancer</source> (<year>2013</year>) <volume>133</volume>(<issue>1</issue>):<fpage>120</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.28015</pub-id><?supplied-pmid 23292955?><pub-id pub-id-type="pmid">23292955</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Tesniere</surname><given-names>A</given-names></name><name><surname>Obeid</surname><given-names>M</given-names></name><name><surname>Ortiz</surname><given-names>C</given-names></name><name><surname>Criollo</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy</article-title>. <source>Nat Med</source> (<year>2007</year>) <volume>13</volume>(<issue>9</issue>):<fpage>1050</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nm1622</pub-id><?supplied-pmid 17704786?><pub-id pub-id-type="pmid">17704786</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reits</surname><given-names>EA</given-names></name><name><surname>Hodge</surname><given-names>JW</given-names></name><name><surname>Herberts</surname><given-names>CA</given-names></name><name><surname>Groothuis</surname><given-names>TA</given-names></name><name><surname>Chakraborty</surname><given-names>M</given-names></name><name><surname>Wansley</surname><given-names>EK</given-names></name><etal/></person-group>
<article-title>Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy</article-title>. <source>J Exp Med</source> (<year>2006</year>) <volume>203</volume>(<issue>5</issue>):<fpage>1259</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20052494</pub-id><?supplied-pmid 16636135?><pub-id pub-id-type="pmid">16636135</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnette</surname><given-names>B</given-names></name><name><surname>Weichselbaum</surname><given-names>RR</given-names></name></person-group>. <article-title>Radiation as an immune modulator</article-title>. <source>Semin Radiat Oncol</source> (<year>2013</year>) <volume>23</volume>(<issue>4</issue>):<fpage>273</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.semradonc.2013.05.009</pub-id><?supplied-pmid 24012341?><pub-id pub-id-type="pmid">24012341</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twyman-Saint</surname><given-names>Victor C</given-names></name><name><surname>Rech</surname><given-names>AJ</given-names></name><name><surname>Maity</surname><given-names>A</given-names></name><name><surname>Rengan</surname><given-names>R</given-names></name><name><surname>Pauken</surname><given-names>KE</given-names></name><name><surname>Stelekati</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer</article-title>. <source>Nature</source> (<year>2015</year>) <volume>520</volume>(<issue>7547</issue>):<fpage>373</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nature14292</pub-id><?supplied-pmid 25754329?><pub-id pub-id-type="pmid">25754329</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louveau</surname><given-names>A</given-names></name><name><surname>Smirnov</surname><given-names>I</given-names></name><name><surname>Keyes</surname><given-names>TJ</given-names></name><name><surname>Eccles</surname><given-names>JD</given-names></name><name><surname>Rouhani</surname><given-names>SJ</given-names></name><name><surname>Peske</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Structural and functional features of central nervous system lymphatic vessels</article-title>. <source>Nature</source> (<year>2015</year>) <volume>523</volume>(<issue>7560</issue>):<fpage>337</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1038/nature14432</pub-id><?supplied-pmid 26030524?><pub-id pub-id-type="pmid">26030524</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsa</surname><given-names>AT</given-names></name><name><surname>Waldron</surname><given-names>JS</given-names></name><name><surname>Panner</surname><given-names>A</given-names></name><name><surname>Crane</surname><given-names>CA</given-names></name><name><surname>Parney</surname><given-names>IF</given-names></name><name><surname>Barry</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma</article-title>. <source>Nat Med</source> (<year>2007</year>) <volume>13</volume>(<issue>1</issue>):<fpage>84</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nm1517</pub-id><?supplied-pmid 17159987?><pub-id pub-id-type="pmid">17159987</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>O</given-names></name><name><surname>Crane</surname><given-names>CA</given-names></name><name><surname>Kaur</surname><given-names>R</given-names></name><name><surname>Safaee</surname><given-names>M</given-names></name><name><surname>Rutkowski</surname><given-names>MJ</given-names></name><name><surname>Parsa</surname><given-names>AT</given-names></name></person-group>. <article-title>Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages</article-title>. <source>Clin Cancer Res</source> (<year>2013</year>) <volume>19</volume>(<issue>12</issue>):<fpage>3165</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3314</pub-id><?supplied-pmid 23613317?><pub-id pub-id-type="pmid">23613317</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Young</surname><given-names>GD</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>McMiller</surname><given-names>TL</given-names></name><etal/></person-group>
<article-title>Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape</article-title>. <source>Sci Transl Med</source> (<year>2012</year>) <volume>4</volume>(<issue>127</issue>):<fpage>127ra37</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3003689</pub-id><?supplied-pmid 22461641?><pub-id pub-id-type="pmid">22461641</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname><given-names>AS</given-names></name><name><surname>Ricken</surname><given-names>G</given-names></name><name><surname>Widhalm</surname><given-names>G</given-names></name><name><surname>Rajky</surname><given-names>O</given-names></name><name><surname>Hainfellner</surname><given-names>JA</given-names></name><name><surname>Birner</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)</article-title>. <source>Clin Neuropathol</source> (<year>2014</year>) <volume>33</volume>(<issue>1</issue>):<fpage>42</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.5414/NP300698</pub-id><?supplied-pmid 24359606?><pub-id pub-id-type="pmid">24359606</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname><given-names>AS</given-names></name><name><surname>Ricken</surname><given-names>G</given-names></name><name><surname>Widhalm</surname><given-names>G</given-names></name><name><surname>Rajky</surname><given-names>O</given-names></name><name><surname>Dieckmann</surname><given-names>K</given-names></name><name><surname>Birner</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases</article-title>. <source>Histopathology</source> (<year>2015</year>) <volume>66</volume>(<issue>2</issue>):<fpage>289</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1111/his.12537</pub-id><?supplied-pmid 25314639?><pub-id pub-id-type="pmid">25314639</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belcaid</surname><given-names>Z</given-names></name><name><surname>Phallen</surname><given-names>JA</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>See</surname><given-names>AP</given-names></name><name><surname>Mathios</surname><given-names>D</given-names></name><name><surname>Gottschalk</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>7</issue>):<fpage>e101764</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0101764</pub-id><?supplied-pmid 25013914?><pub-id pub-id-type="pmid">25013914</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Burnette</surname><given-names>B</given-names></name><name><surname>Weicheslbaum</surname><given-names>RR</given-names></name><name><surname>Fu</surname><given-names>YX</given-names></name></person-group>. <article-title>Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression</article-title>. <source>Oncoimmunology</source> (<year>2014</year>) <volume>3</volume>:<fpage>e28499</fpage>.<pub-id pub-id-type="doi">10.4161/onci.28499</pub-id><?supplied-pmid 25050217?><pub-id pub-id-type="pmid">25050217</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smilowitz</surname><given-names>HM</given-names></name><name><surname>Micca</surname><given-names>PL</given-names></name><name><surname>Sasso</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Dyment</surname><given-names>N</given-names></name><name><surname>Xue</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma</article-title>. <source>Cancer Immunol Immunother</source> (<year>2016</year>) <volume>65</volume>(<issue>2</issue>):<fpage>127</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1007/s00262-015-1772-7</pub-id><?supplied-pmid 26660339?><pub-id pub-id-type="pmid">26660339</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van vulpen</surname><given-names>M</given-names></name><name><surname>Kal</surname><given-names>HB</given-names></name><name><surname>Taphoorn</surname><given-names>MJ</given-names></name><name><surname>El-sharouni</surname><given-names>SY</given-names></name></person-group>. <article-title>Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review)</article-title>. <source>Oncol Rep</source> (<year>2002</year>) <volume>9</volume>(<issue>4</issue>):<fpage>683</fpage>&#x02013;<lpage>8</lpage>.<?supplied-pmid 12066192?><pub-id pub-id-type="pmid">12066192</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamell</surname><given-names>EF</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Gnjatic</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Brownell</surname><given-names>I</given-names></name></person-group>. <article-title>The abscopal effect associated with a systemic anti-melanoma immune response</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2013</year>) <volume>85</volume>(<issue>2</issue>):<fpage>293</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.03.017</pub-id><?supplied-pmid 22560555?><pub-id pub-id-type="pmid">22560555</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiniker</surname><given-names>SM</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>DT</given-names></name><name><surname>Jones</surname><given-names>JC</given-names></name><name><surname>Mollick</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>A systemic complete response of metastatic melanoma to local radiation and immunotherapy</article-title>. <source>Transl Oncol</source> (<year>2012</year>) <volume>5</volume>(<issue>6</issue>):<fpage>404</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1593/tlo.12280</pub-id><?supplied-pmid 23323154?><pub-id pub-id-type="pmid">23323154</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>EB</given-names></name><name><surname>Demaria</surname><given-names>S</given-names></name><name><surname>Schiff</surname><given-names>PB</given-names></name><name><surname>Chachoua</surname><given-names>A</given-names></name><name><surname>Formenti</surname><given-names>SC</given-names></name></person-group>
<article-title>An abscopal response to radiation and ipilimumab in a patient with metastatic non&#x02013;small cell lung cancer</article-title>. <source>Cancer Immunol Res</source> (<year>2013</year>) <volume>1</volume>(<issue>6</issue>):<fpage>365</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0115</pub-id><pub-id pub-id-type="pmid">24563870</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>ED</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Bossi</surname><given-names>A</given-names></name><name><surname>van den Eertwegh</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial</article-title>. <source>Lancet Oncol</source> (<year>2014</year>) <volume>15</volume>(<issue>7</issue>):<fpage>700</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/S1470-2045(14)70189-5</pub-id><?supplied-pmid 24831977?><pub-id pub-id-type="pmid">24831977</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slovin</surname><given-names>SF</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Tejwani</surname><given-names>S</given-names></name><name><surname>Harzstark</surname><given-names>A</given-names></name><name><surname>Alumkal</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study</article-title>. <source>Ann Oncol</source> (<year>2013</year>) <volume>24</volume>(<issue>7</issue>):<fpage>1813</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1093/annonc/mdt107</pub-id><?supplied-pmid 23535954?><pub-id pub-id-type="pmid">23535954</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerritsen</surname><given-names>W</given-names></name><name><surname>Kwon</surname><given-names>E</given-names></name><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Bossi</surname><given-names>A</given-names></name><name><surname>Van Den Eertwegh</surname><given-names>A</given-names></name><name><surname>Logothetis</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>CA184-043: a randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (PTS) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (IPI) versus placebo (PBO), each following single-dose radiotherapy (RT)</article-title>. <source>European Cancer Congress</source> (<year>2013</year>) Abstract 2850.</mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KR</given-names></name><name><surname>Lawson</surname><given-names>DH</given-names></name><name><surname>Kudchadkar</surname><given-names>RR</given-names></name><name><surname>Carthon</surname><given-names>BC</given-names></name><name><surname>Oliver</surname><given-names>DE</given-names></name><name><surname>Okwan-Duodu</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases</article-title>. <source>Neuro Oncol</source> (<year>2015</year>) <volume>17</volume>(<issue>10</issue>):<fpage>1312</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1093/neuonc/nov093</pub-id><?supplied-pmid 26014049?><pub-id pub-id-type="pmid">26014049</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knisely</surname><given-names>JP</given-names></name><name><surname>Yu</surname><given-names>JB</given-names></name><name><surname>Flanigan</surname><given-names>J</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>Kluger</surname><given-names>HM</given-names></name><name><surname>Chiang</surname><given-names>VL</given-names></name></person-group>. <article-title>Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival</article-title>. <source>J Neurosurg</source> (<year>2012</year>) <volume>117</volume>(<issue>2</issue>):<fpage>227</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.3171/2012.5.JNS111929</pub-id><?supplied-pmid 22702482?><pub-id pub-id-type="pmid">22702482</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silk</surname><given-names>AW</given-names></name><name><surname>Bassetti</surname><given-names>MF</given-names></name><name><surname>West</surname><given-names>BT</given-names></name><name><surname>Tsien</surname><given-names>CI</given-names></name><name><surname>Lao</surname><given-names>CD</given-names></name></person-group>. <article-title>Ipilimumab and radiation therapy for melanoma brain metastases</article-title>. <source>Cancer Med</source> (<year>2013</year>) <volume>2</volume>(<issue>6</issue>):<fpage>899</fpage>&#x02013;<lpage>906</lpage>.<pub-id pub-id-type="doi">10.1002/cam4.140</pub-id><?supplied-pmid 24403263?><pub-id pub-id-type="pmid">24403263</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiess</surname><given-names>AP</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Barker</surname><given-names>CA</given-names></name><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Tabar</surname><given-names>V</given-names></name><name><surname>Huse</surname><given-names>JT</given-names></name><etal/></person-group>
<article-title>Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2015</year>) <volume>92</volume>(<issue>2</issue>):<fpage>368</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.01.004</pub-id><?supplied-pmid 25754629?><pub-id pub-id-type="pmid">25754629</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Amin</surname><given-names>A</given-names></name><name><surname>Minor</surname><given-names>D</given-names></name><name><surname>Siegel</surname><given-names>J</given-names></name><name><surname>Berman</surname><given-names>D</given-names></name><name><surname>O&#x02019;day</surname><given-names>SJ</given-names></name></person-group>. <article-title>Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial</article-title>. <source>Melanoma Res</source> (<year>2011</year>) <volume>21</volume>(<issue>6</issue>):<fpage>530</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1097/CMR.0b013e32834d3d88</pub-id><?supplied-pmid 22051508?><pub-id pub-id-type="pmid">22051508</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>KK</given-names></name><name><surname>Hara</surname><given-names>W</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group>. <article-title>Combining immunotherapy with radiation for the treatment of glioblastoma</article-title>. <source>J Neurooncol</source> (<year>2015</year>) <volume>123</volume>(<issue>3</issue>):<fpage>459</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1007/s11060-015-1762-9</pub-id><?supplied-pmid 25877468?><pub-id pub-id-type="pmid">25877468</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>PY</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Phuphanich</surname><given-names>S</given-names></name><name><surname>Aiken</surname><given-names>R</given-names></name><name><surname>Landolfi</surname><given-names>JC</given-names></name><name><surname>Curry</surname><given-names>WT</given-names></name><etal/></person-group>
<article-title>A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients</article-title>. <conf-name>ASCO Annual Meeting Proceedings</conf-name> (Vol. <volume>32</volume>). <conf-loc>Chicago, IL</conf-loc>: <conf-sponsor>J Clin Oncol (Meeting Abstracts)</conf-sponsor> (<year>2014</year>). <fpage>2005</fpage> p. May 20.</mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El andaloussi</surname><given-names>A</given-names></name><name><surname>Lesniak</surname><given-names>MS</given-names></name></person-group>. <article-title>An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme</article-title>. <source>Neuro Oncol</source> (<year>2006</year>) <volume>8</volume>(<issue>3</issue>):<fpage>234</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1215/15228517-2006-006</pub-id><?supplied-pmid 16723631?><pub-id pub-id-type="pmid">16723631</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>CA</given-names></name><name><surname>Ahn</surname><given-names>BJ</given-names></name><name><surname>Han</surname><given-names>SJ</given-names></name><name><surname>Parsa</surname><given-names>AT</given-names></name></person-group>. <article-title>Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy</article-title>. <source>Neuro Oncol</source> (<year>2012</year>) <volume>14</volume>(<issue>5</issue>):<fpage>584</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1093/neuonc/nos014</pub-id><?supplied-pmid 22406925?><pub-id pub-id-type="pmid">22406925</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>JF</given-names></name><name><surname>Idema</surname><given-names>AJ</given-names></name><name><surname>Bol</surname><given-names>KF</given-names></name><name><surname>Grotenhuis</surname><given-names>JA</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Wesseling</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Prognostic significance and mechanism of Treg infiltration in human brain tumors</article-title>. <source>J Neuroimmunol</source> (<year>2010</year>) <volume>225</volume>(<issue>1&#x02013;2</issue>):<fpage>195</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.jneuroim.2010.05.020</pub-id><?supplied-pmid 20537408?><pub-id pub-id-type="pmid">20537408</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fuller</surname><given-names>G</given-names></name><name><surname>Fokt</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Hypoxia potentiates glioma-mediated immunosuppression</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>(<issue>1</issue>):<fpage>e16195</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0016195</pub-id><?supplied-pmid 21283755?><pub-id pub-id-type="pmid">21283755</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname><given-names>AS</given-names></name><name><surname>Kiesel</surname><given-names>B</given-names></name><name><surname>Widhalm</surname><given-names>G</given-names></name><name><surname>Rajky</surname><given-names>O</given-names></name><name><surname>Ricken</surname><given-names>G</given-names></name><name><surname>W&#x000f6;hrer</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma</article-title>. <source>Neuro Oncol</source> (<year>2015</year>) <volume>17</volume>(<issue>8</issue>):<fpage>1064</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1093/neuonc/nou307</pub-id><?supplied-pmid 25355681?><pub-id pub-id-type="pmid">25355681</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>A</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Zaretsky</surname><given-names>JM</given-names></name><name><surname>Desrichard</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title>. <source>N Engl J Med</source> (<year>2014</year>) <volume>371</volume>(<issue>23</issue>):<fpage>2189</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id><?supplied-pmid 25409260?><pub-id pub-id-type="pmid">25409260</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Snyder</surname><given-names>A</given-names></name><name><surname>Kvistborg</surname><given-names>P</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Havel</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</article-title>. <source>Science</source> (<year>2015</year>) <volume>348</volume>(<issue>6230</issue>):<fpage>124</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id><?supplied-pmid 25765070?><pub-id pub-id-type="pmid">25765070</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Sampson</surname><given-names>JH</given-names></name></person-group>. <article-title>Prospects of immune checkpoint modulators in the treatment of glioblastoma</article-title>. <source>Nat Rev Neurol</source> (<year>2015</year>) <volume>11</volume>(<issue>9</issue>):<fpage>504</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1038/nrneurol.2015.139</pub-id><?supplied-pmid 26260659?><pub-id pub-id-type="pmid">26260659</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>DA</given-names></name><name><surname>Schuster</surname><given-names>JM</given-names></name><name><surname>Tran</surname><given-names>DD</given-names></name><name><surname>Fink</surname><given-names>KL</given-names></name><name><surname>Nabors</surname><given-names>LB</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>107 ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma</article-title>. <source>Neurosurgery</source> (<year>2015</year>) <volume>62</volume>:<fpage>198</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1227/01.neu.0000467069.86811.3f</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>JS</given-names></name><name><surname>Ung</surname><given-names>TH</given-names></name><name><surname>Neira</surname><given-names>JA</given-names></name><name><surname>Canoll</surname><given-names>P</given-names></name><name><surname>Bruce</surname><given-names>JN</given-names></name></person-group>. <article-title>Biomarkers for glioma immunotherapy: the next generation</article-title>. <source>J Neurooncol</source> (<year>2015</year>) <volume>123</volume>(<issue>3</issue>):<fpage>359</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1007/s11060-015-1746-9</pub-id><?supplied-pmid 25724916?><pub-id pub-id-type="pmid">25724916</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garzon</surname><given-names>R</given-names></name><name><surname>Marcucci</surname><given-names>G</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group>. <article-title>Targeting microRNAs in cancer: rationale, strategies and challenges</article-title>. <source>Nat Rev Drug Discov</source> (<year>2010</year>) <volume>9</volume>(<issue>10</issue>):<fpage>775</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1038/nrd3179</pub-id><?supplied-pmid 20885409?><pub-id pub-id-type="pmid">20885409</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group>. <article-title>Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles</article-title>. <source>J Neurol Sci</source> (<year>2015</year>) <volume>348</volume>(<issue>1&#x02013;2</issue>):<fpage>181</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.jns.2014.11.036</pub-id><?supplied-pmid 25510379?><pub-id pub-id-type="pmid">25510379</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>P</given-names></name><name><surname>Wischhusen</surname><given-names>J</given-names></name><name><surname>Happold</surname><given-names>C</given-names></name><name><surname>Chandran</surname><given-names>PA</given-names></name><name><surname>Hofer</surname><given-names>S</given-names></name><name><surname>Eisele</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>A specific miRNA signature in the peripheral blood of glioblastoma patients</article-title>. <source>J Neurochem</source> (<year>2011</year>) <volume>118</volume>(<issue>3</issue>):<fpage>449</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07307.x</pub-id><?supplied-pmid 21561454?><pub-id pub-id-type="pmid">21561454</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manterola</surname><given-names>L</given-names></name><name><surname>Guruceaga</surname><given-names>E</given-names></name><name><surname>G&#x000e1;llego P&#x000e9;rez-Larraya</surname><given-names>J</given-names></name><name><surname>Gonz&#x000e1;lez-Huarriz</surname><given-names>M</given-names></name><name><surname>Jauregui</surname><given-names>P</given-names></name><name><surname>Tejada</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool</article-title>. <source>Neuro Oncol</source> (<year>2014</year>) <volume>16</volume>(<issue>4</issue>):<fpage>520</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/neuonc/not218</pub-id><?supplied-pmid 24435880?><pub-id pub-id-type="pmid">24435880</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teplyuk</surname><given-names>NM</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Gabriely</surname><given-names>G</given-names></name><name><surname>Giese</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Smolsky</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity</article-title>. <source>Neuro Oncol</source> (<year>2012</year>) <volume>14</volume>(<issue>6</issue>):<fpage>689</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="doi">10.1093/neuonc/nos074</pub-id><?supplied-pmid 22492962?><pub-id pub-id-type="pmid">22492962</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsen</surname><given-names>SB</given-names></name><name><surname>Obad</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>NF</given-names></name><name><surname>Stenvang</surname><given-names>J</given-names></name><name><surname>Kauppinen</surname><given-names>S</given-names></name></person-group>
<article-title>The therapeutic potential of microRNAs in cancer</article-title>. <source>Cancer J</source> (<year>2012</year>) <volume>18</volume>(<issue>3</issue>):<fpage>275</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1097/PPO.0b013e318258b5d6</pub-id><pub-id pub-id-type="pmid">22647365</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>W&#x000fc;rdinger</surname><given-names>T</given-names></name><name><surname>Tannous</surname><given-names>BA</given-names></name><name><surname>Saydam</surname><given-names>O</given-names></name><name><surname>Skog</surname><given-names>J</given-names></name><name><surname>Grau</surname><given-names>S</given-names></name><name><surname>Soutschek</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells</article-title>. <source>Cancer Cell</source> (<year>2008</year>) <volume>14</volume>(<issue>5</issue>):<fpage>382</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1016/j.ccr.2008.10.005</pub-id><?supplied-pmid 18977327?><pub-id pub-id-type="pmid">18977327</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Nduom</surname><given-names>EK</given-names></name><name><surname>Kong</surname><given-names>LY</given-names></name><etal/></person-group>
<article-title>MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints</article-title>. <source>Neuro Oncol</source> (<year>2016</year>) <volume>18</volume>(<issue>5</issue>):<fpage>639</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1093/neuonc/nov292</pub-id><pub-id pub-id-type="pmid">26658052</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustafson</surname><given-names>MP</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>LaPlant</surname><given-names>B</given-names></name><name><surname>Liwski</surname><given-names>CJ</given-names></name><name><surname>Maas</surname><given-names>ML</given-names></name><name><surname>League</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Immune monitoring using the predictive power of immune profiles</article-title>. <source>J Immunother Cancer</source> (<year>2013</year>) <volume>1</volume>:<fpage>7</fpage>.<pub-id pub-id-type="doi">10.1186/2051-1426-1-7</pub-id><?supplied-pmid 25512872?><pub-id pub-id-type="pmid">25512872</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Harview</surname><given-names>CL</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Taylor</surname><given-names>EJ</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title>. <source>Nature</source> (<year>2014</year>) <volume>515</volume>(<issue>7528</issue>):<fpage>568</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1038/nature13954</pub-id><?supplied-pmid 25428505?><pub-id pub-id-type="pmid">25428505</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>T</given-names></name><name><surname>Wallden</surname><given-names>B</given-names></name><name><surname>Schaper</surname><given-names>C</given-names></name><name><surname>Ferree</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Analytical validation of the PAM50-based prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin-embedded breast tumor specimens</article-title>. <source>BMC Cancer</source> (<year>2014</year>) <volume>14</volume>:<fpage>177</fpage>.<pub-id pub-id-type="doi">10.1186/1471-2407-14-177</pub-id><?supplied-pmid 24625003?><pub-id pub-id-type="pmid">24625003</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name><name><surname>Berglund</surname><given-names>A</given-names></name><name><surname>Eschrich</surname><given-names>SA</given-names></name><name><surname>Schabath</surname><given-names>MB</given-names></name><etal/></person-group>
<article-title>Radiomics: the process and the challenges</article-title>. <source>Magn Reson Imaging</source> (<year>2012</year>) <volume>30</volume>(<issue>9</issue>):<fpage>1234</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1016/j.mri.2012.06.010</pub-id><?supplied-pmid 22898692?><pub-id pub-id-type="pmid">22898692</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambin</surname><given-names>P</given-names></name><name><surname>Rios-Velazquez</surname><given-names>E</given-names></name><name><surname>Leijenaar</surname><given-names>R</given-names></name><name><surname>Carvalho</surname><given-names>S</given-names></name><name><surname>van Stiphout</surname><given-names>RG</given-names></name><name><surname>Granton</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Radiomics: extracting more information from medical images using advanced feature analysis</article-title>. <source>Eur J Cancer</source> (<year>2012</year>) <volume>48</volume>(<issue>4</issue>):<fpage>441</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.ejca.2011.11.036</pub-id><?supplied-pmid 22257792?><pub-id pub-id-type="pmid">22257792</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinn</surname><given-names>PO</given-names></name><name><surname>Mahajan</surname><given-names>B</given-names></name><name><surname>Sathyan</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Majumder</surname><given-names>S</given-names></name><name><surname>Jolesz</surname><given-names>FA</given-names></name><etal/></person-group>
<article-title>Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>(<issue>10</issue>):<fpage>e25451</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0025451</pub-id><?supplied-pmid 21998659?><pub-id pub-id-type="pmid">21998659</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>L</given-names></name><name><surname>Goldgof</surname><given-names>D</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Balagurunathan</surname><given-names>Y</given-names></name><name><surname>Gillies</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results</article-title>. <source>Transl Oncol</source> (<year>2014</year>) <volume>7</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1593/tlo.13730</pub-id><?supplied-pmid 24772202?><pub-id pub-id-type="pmid">24772202</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colaco</surname><given-names>RJ</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Kluger</surname><given-names>HM</given-names></name><name><surname>Yu</surname><given-names>JB</given-names></name><name><surname>Chiang</surname><given-names>VL</given-names></name></person-group>. <article-title>Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?</article-title>
<source>J Neurosurg</source> (<year>2016</year>) <volume>125</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.3171/2015.6.JNS142763</pub-id><?supplied-pmid 26544782?><pub-id pub-id-type="pmid">26544782</pub-id></mixed-citation></ref></ref-list></back></article>